Efficacy and Safety of a Nanoparticle Therapeutic Vaccine in Patients with Chronic Hepatitis B: A Randomized Clinical Trial.

Lai Wei,Tingting Zhao,Ji Zhang,Qing Mao,Guozhong Gong,Yongtao Sun,Yongping Chen,Maorong Wang,Deming Tan,Zuojiong Gong,Baosen Li,Junqi Niu,Shuchen Li,Huanyu Gong,Liyun Zou,Wei Zhou,Zhengcai Jia,Yan Tang,Lei Fei,Yang Hu,Xiaoyun Shang,Junfeng Han,Bei Zhang,Yuzhang Wu

DOI: https://doi.org/10.1002/hep.32109

IF: 17.298

2021-01-01

Hepatology

Abstract:Background and Aim HBV DNA can be reduced using antiviral drugs in patients with chronic hepatitis B (CHB); however, the rate of HBeAg seroconversion remains low. A clinical trial was conducted to assess the efficacy and safety of a de novo designed liposome-based nanoparticle lipopeptide vaccine, epsilon PA-44, for CHB. Approach and Results A two-stage phase 2 trial, which included a 76-week, randomized, double-blind, placebo-controlled trial (stage 1) and a 68-week open-label extension (stage 2), was conducted in 15 centers across China (Clinicaltrials.gov No. NCT00869778). In stage 1, 360 human leukocyte antigen A2 (HLA-A2)-positive and HBeAg-positive patients were randomly and equally distributed to receive six subcutaneous injections of 600 mu g or 900 mu g epsilon PA-44 or placebo at week 0, 4, 8, 12, 20, and 28. In stage 2, 183 patients received extended 900 mu g epsilon PA-44, and 26 patients were observed for relapse without further treatment. The primary endpoint was the percentage of patients with HBeAg seroconversion at week 76. At week 76, patients receiving 900 mu g epsilon PA-44 achieved significantly higher HBeAg seroconversion rate (38.8%) versus placebo (20.2%) (95% CI, 6.9-29.6%; p = 0.002). With a combined endpoint of HBeAg seroconversion, alanine aminotransferase normalization and HBV DNA < 2,000 IU/mL, both 900 mu g (18.1%) and 600 mu g (14.3%), resulted in significantly higher rate versus placebo (5.0%) (p = 0.002 and p = 0.02, respectively) at week 76. In stage 2, none (0 of 20) of 900 mu g epsilon PA-44-treated patients experienced serologic relapse. The safety profile of epsilon PA-44 was comparable to that of placebo. Conclusions Among HLA-A2-positive patients with progressive CHB, a finite duration of 900 mu g epsilon PA-44 monotherapy resulted in significantly higher HBeAg seroconversion rate than placebo and sustained off-treatment effect. A phase 3 trial is ongoing (ChiCTR2100043708).